Patents by Inventor Michael J. Munchhof

Michael J. Munchhof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazole compounds as transforming growth factor (TGF) inhibitors
    Patent number: 7053095
    Abstract: Novel triazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: May 30, 2006
    Assignee: Pfizer Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors
    Patent number: 7030125
    Abstract: Novel isothiazole and isoxazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: April 18, 2006
    Assignee: Pfizer, Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6962993
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: November 8, 2005
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrazole compounds as transforming growth factor (TGF) inhibitors
    Patent number: 6958354
    Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: October 25, 2005
    Assignee: Pfizer Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6956041
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: October 18, 2005
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Chiral salt resolution
    Publication number: 20040229923
    Abstract: A method for resolving enantiomers of a compound containing the structure of the formula: 1
    Type: Application
    Filed: June 16, 2004
    Publication date: November 18, 2004
    Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
  • Novel pyrazine compounds as transforming growth factor (TGF) compounds
    Publication number: 20040180905
    Abstract: Novel pyrazine compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: March 10, 2004
    Publication date: September 16, 2004
    Applicant: Pfizer Inc
    Inventor: Michael J. Munchhof
  • Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors
    Publication number: 20040176390
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: February 20, 2004
    Publication date: September 9, 2004
    Applicant: Pfizer Inc
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • Isothiazole derivatives
    Publication number: 20040147574
    Abstract: Novel isothiazole compounds, including derivatives thereof, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, hyperproliferative disorders and fibrotic diseases.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 29, 2004
    Applicant: Pfizer Inc
    Inventor: Michael J. Munchhof
  • Novel pyrazole compounds as transforming growth factor (TGF) inhibitors
    Publication number: 20040116474
    Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Application
    Filed: September 17, 2003
    Publication date: June 17, 2004
    Applicant: Pfizer Inc
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors
    Publication number: 20040116473
    Abstract: Novel isothiazole and isoxazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Application
    Filed: September 17, 2003
    Publication date: June 17, 2004
    Applicant: Pfizer Inc
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
    Publication number: 20040110797
    Abstract: Novel oxazole and thiazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: September 17, 2003
    Publication date: June 10, 2004
    Applicant: Pfizer Inc
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Novel triazole compounds as transforming growth factors (TGF) inhibitors
    Publication number: 20040110798
    Abstract: Novel triazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: September 17, 2003
    Publication date: June 10, 2004
    Applicant: Pfizer Inc
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Novel imidazole compounds as transforming growth factor (TGF) inhibitors
    Publication number: 20040106608
    Abstract: Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: September 17, 2003
    Publication date: June 3, 2004
    Applicant: Pfizer Inc
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Pyrrolo[2,3-D]pyrimidine compounds
    Publication number: 20040053947
    Abstract: A compound of the formula 1
    Type: Application
    Filed: August 13, 2003
    Publication date: March 18, 2004
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6696567
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: February 24, 2004
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20030220353
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 16, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6627754
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: September 30, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Chiral salt resolution
    Publication number: 20030073719
    Abstract: A method for resolving enantiomers of a compound containing the structure of the formula: 1
    Type: Application
    Filed: May 23, 2002
    Publication date: April 17, 2003
    Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20020068746
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 25, 2001
    Publication date: June 6, 2002
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof